# US 2012/0252027 A1 · Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252027 A1
- Document ID: US20120252027A1
- Status: Published application
- Kind: A1
- Application number: 13/515,454
- Filed: 2010-12-09
- Published: 2012-10-04
- Earliest claimed: 2009-12-17
- Assignees: Sirna Therapeutics, Inc.
- Inventors: Gabor Butora; Ian W. Davies; William Michael Flanagan; Wenlang Fu; Denise M. Kenski; Ning Qi
- Web page: https://patentgrep.com/patent/US20120252027A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/32: of the sugar
- C12N 2310/322: 2'-R Modification
- C12N 2310/331: Universal or degenerate base
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.

## Claims

### Claim 1

A method for an efficient and streamlined process for the evaluation of novel chemical modifications in an siRNA, said method comprising: a) generating a siRNA oligomer with 1 or more sugar un-modified universal base containing nucleosides; b) obtaining position-specific data to create a baseline data; c) generating a siRNA oligomer with 1 or more sugar modified universal base containing nucleosides; and d) obtaining position-specific data and comparing that data to the baseline data.

### Claim 2

A siRNA which contains a 2′-sugar modification(s) at positions 3, 5, 6, 8, 15, 17 and 19 wherein the 2′-sugar modification(s) is represented in Formula B,
wherein,
p is 0, 1, 2 or 3;
Ring K is aryl, heterocyclyl or a (C3-C8)cycloalkyl;
R1 is independently selected from: OH, COOH, CF3, NO2, halo, (C1-C6)alkyl, O(C1-C6)alkyl, aryl, O-aryl, heteroaryl, O-heteroaryl, heterocyclyl or O-heterocyclyl, wherein said alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with from one to three substituents selected from halo and (C1-C6)alkyl;
R2 is selected from: a canonical or universal base; and
R3 is selected from H and (C1-C6)alkyl;
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 3

A siRNA which contains a 2′-sugar modification(s) at positions 3, 5, 6, 8, 15, 17 or 19 wherein the 2′-sugar modification(s) is represented in Formula B,
wherein,
p is 0, 1, 2 or 3;
Ring K is aryl, heterocyclyl or a (C3-C8)cycloalkyl;
R1 is independently selected from: OH, COOH, CF3, NO2, halo, (C1-C6)alkyl, O(C1-C6)alkyl, aryl, O-aryl, heteroaryl, O-heteroaryl, heterocyclyl or O-heterocyclyl, wherein said alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with from one to three substituents selected from halo and (C1-C6)alkyl;
R2 is selected from: a canonical or universal base; and
R3 is selected from H and (C1-C6)alkyl;
or a pharmaceutically acceptable salt or stereoisomer thereof.
